Download MendeleySynthesis, SAR study, and biological evaluation of novel 2,3-dihydro-1H-imidazo[1,2-a]benzimidazole derivatives as phosphodiesterase 10A inhibitors.
Chino, A., Honda, S., Morita, M., Yonezawa, K., Hamaguchi, W., Amano, Y., Moriguchi, H., Yamazaki, M., Aota, M., Tomishima, M., Masuda, N.(2019) Bioorg Med Chem 27: 3692-3706
- PubMed: 31301949
- DOI: https://doi.org/10.1016/j.bmc.2019.07.010
- Primary Citation of Related Structures:
6KDX, 6KDZ, 6KE0 - PubMed Abstract:
Phosphodiesterase 10A (PDE10A) inhibitors were designed and synthesized based on the dihydro-imidazobenzimidazole scaffold. Compound 5a showed moderate inhibitory activity and good permeability, but unfavorable high P-glycoprotein (P-gp) liability for brain penetration. We performed an optimization study to improve both the P-gp efflux ratio and PDE10A inhibitory activity. As a result, 6d was identified with improved P-gp liability and high PDE10A inhibitory activity. Compound 6d also showed satisfactory brain penetration, suppressed phencyclidine-induced hyperlocomotion and improved MK-801-induced working memory deficit.
Organizational Affiliation:
Functional Molecules, Modality Research Laboratories, Drug Discovery Research, Astellas Pharma Inc., 21, Miyukigaoka, Tsukuba, Ibaraki 305-8585, Japan. Electronic address: ayaka.chino@astellas.com.
